Incentify's Series A funding of $9.5 million will enhance its AI-driven platform, which helps companies find and utilize tax credits, addressing an immense $1.2 trillion incentive gap.
"This funding will further turbocharge the development of our next-generation AI drug design engine, help us advance our own programs into clinical development, and is a significant step forward towards our mission of one day solving all disease with the help of AI," Demis Hassabis, Isomorphic Labs founder and chief executive, said in a statement.
Funding is harder to secure, and profitability has become the real measure of success. With this investment, we are focused on scaling sustainably and reaching break-even this year.
OpenAI is the hottest deal in venture capital history," said Joe Aaron, founding partner at TRAC. But, Aaron cautioned that investors should be wary of a company that's become so synonymous with corporate turmoil.